AR092216A1 - Formulaciones estables de anticuerpos contra tslp - Google Patents
Formulaciones estables de anticuerpos contra tslpInfo
- Publication number
- AR092216A1 AR092216A1 ARP130102994A ARP130102994A AR092216A1 AR 092216 A1 AR092216 A1 AR 092216A1 AR P130102994 A ARP130102994 A AR P130102994A AR P130102994 A ARP130102994 A AR P130102994A AR 092216 A1 AR092216 A1 AR 092216A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- seq
- approximately
- antibodies against
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulaciones estables de anticuerpos contra TSLP humana, o sus fragmentos de unión a antígeno y un tampón de histidina. Reivindicación 6: La formulación de la reivindicación 5, en la que la formulación está liofilizada. Reivindicación 10: La formulación de la reivindicación 6, en la que después de la reconstitución la formulación comprende: a) 40 - 100 mg/ml de anticuerpo anti-TSLP, o fragmento de unión a antígeno del mismo; b) aproximadamente 70 mg/ml de sacarosa; c) aproximadamente 0,2 mg/ml de polisorbato 80; y d) tampón de Histidina aproximadamente 10 mM a un pH de aproximadamente 5,0 - 6,0. Reivindicación 13: La formulación de una cualquiera de las reivindicaciones anteriores, en la que el anticuerpo, o fragmento de unión a antígeno del mismo, comprende: (a) una cadena ligera que comprende la secuencia de aminoácidos de la SEC ID Nº 1 y una cadena pesada que comprende la secuencia de aminoácidos de la SEC ID Nº 2; o (b) una región variable de cadena ligera que comprende las secuencias CDR de las SEC ID Nº 3, 4 y 5 y una región variable de cadena pesada que comprende las secuencias CDR de las SEC ID Nº 6, 7 y 8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261692257P | 2012-08-23 | 2012-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092216A1 true AR092216A1 (es) | 2015-04-08 |
Family
ID=49162212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102994A AR092216A1 (es) | 2012-08-23 | 2013-08-23 | Formulaciones estables de anticuerpos contra tslp |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140227250A1 (es) |
| AR (1) | AR092216A1 (es) |
| TW (1) | TW201420601A (es) |
| WO (1) | WO2014031718A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| AU2016320748B2 (en) | 2015-09-09 | 2019-05-02 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies |
| CA2996635A1 (en) | 2015-09-09 | 2017-03-16 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
| AU2016348391A1 (en) | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
| JP2018535242A (ja) * | 2015-11-30 | 2018-11-29 | メディミューン，エルエルシー | 高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比 |
| MX2018007520A (es) | 2015-12-18 | 2018-08-01 | Astellas Pharma Inc | Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. |
| CA3061050A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US20190225689A1 (en) * | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
| EP3927729A4 (en) | 2019-02-18 | 2023-10-11 | Eli Lilly and Company | THERAPEUTIC ANTIBODY FORMULATION |
| JP2022535808A (ja) * | 2019-06-04 | 2022-08-10 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用 |
| CN114887053A (zh) * | 2019-11-29 | 2022-08-12 | 康诺亚生物医药科技（成都）有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
| CA3162569A1 (en) * | 2020-01-24 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CR20220457A (es) * | 2020-02-13 | 2023-01-09 | Amgen Inc | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria |
| MX2023006596A (es) * | 2020-12-03 | 2023-06-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma. |
| CN116897053A (zh) * | 2021-03-03 | 2023-10-17 | 正大天晴药业集团股份有限公司 | 含抗tslp抗体的药物组合物 |
| EP4326762A2 (en) * | 2021-04-23 | 2024-02-28 | Amgen Inc. | Modified anti-tslp antibodies |
| CN117203233A (zh) * | 2021-04-23 | 2023-12-08 | 美国安进公司 | 抗tslp抗体组合物及其用途 |
| WO2024092064A1 (en) * | 2022-10-26 | 2024-05-02 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JP5149470B2 (ja) | 1999-02-22 | 2013-02-20 | バクスター・インターナショナル・インコーポレイテッド | 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物 |
| JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ，インコーポレイティド | ＩｇＧ抗体の安定な凍結乾燥医薬製剤 |
| EP2129690A1 (en) | 2006-12-14 | 2009-12-09 | Schering Corporation | Engineered anti-tslp antibody |
| CA2779384C (en) | 2009-11-04 | 2018-02-27 | Schering Corporation | Engineered anti-tslp antibody |
| EA033387B1 (ru) * | 2012-01-23 | 2019-10-31 | Regeneron Pharma | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 |
-
2013
- 2013-08-21 WO PCT/US2013/055931 patent/WO2014031718A1/en active Application Filing
- 2013-08-21 US US13/972,157 patent/US20140227250A1/en not_active Abandoned
- 2013-08-23 TW TW102130397A patent/TW201420601A/zh unknown
- 2013-08-23 AR ARP130102994A patent/AR092216A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140227250A1 (en) | 2014-08-14 |
| WO2014031718A1 (en) | 2014-02-27 |
| TW201420601A (zh) | 2014-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092216A1 (es) | Formulaciones estables de anticuerpos contra tslp | |
| CY1122669T1 (el) | Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| AR122771A2 (es) | Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped | |
| PE20150605A1 (es) | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| PE20240813A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodo para su uso | |
| AR103442A1 (es) | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| ES2676205T3 (es) | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20120341A1 (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t | |
| PE20130393A1 (es) | Anticuerpos con union de antigenos dependiente de ph | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| IL242372B2 (en) | Anti-4-IL/anti-IL-13 bi-specific antibody preparations | |
| AR099812A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
| PE20121691A1 (es) | Formulacion de anticuerpos y regimenes terapeuticos | |
| NZ705178A (en) | Anti-prolactin receptor antibody formulations | |
| PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |